AIDS - Cytomegaloviral retinitis Cytomegalovirus infection, In high risk kidney, heart, or kidney-pancreas transplant patients; Prophylaxis
Black Box Warning: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow failure including aplastic anemia have been reported in patients treated with valganciclovir hydrochloride. Based on animal and limited human data, it may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females. Based on animal data, potential to cause birth defects in humans. and cancers in humans.
Ophthalmic follow-up examination at least every 4-6 weeks during treatment.
Perform CBC with differential and platelet counts frequently.
Perform pregnancy testing before initiating therapy in females.
Monitor renal function, serum creatinine.
Common
Serious
Antimicrobial class: Antiviral, Nucleoside analog
Pregnancy category: C
Average serum half life: 4 hours (Ganciclovir)
Precautions: Absolute neutrophil count <500 cells/mcL, hemoglobin <8 g/dL, or platelet count <25,000/mcL; do not use.
Dose reduction recommended in renal impairment; not recommended in hemodialysis.
Consider hematopoietic growth factor treatment in patients with severe leukopenia, neutropenia, anemia, or thrombocytopenia.
항생제
